Low liver @entity2693 among cirrhotic XXXX with hepatitis B after prolonged treatment with @entity2353 analogs.

@entity1 @entity2353 @entity82 @entity377 @entity6194 @entity2693
OBJECTIVE: Case reports and short-term clinical trials have suggested that treatment for @entity6194 ( @entity6194 ) may lead to improvement of @entity82 . The aim of the present study was to measure liver @entity2693 in @entity1 diagnosed with advanced @entity82 or @entity82 prior to prolonged treatment with @entity2353 or @entity377 analogs (NUCs) for @entity6194 . MATERIALS AND METHODS: @entity1 with @entity6194 and advanced @entity82 or @entity82 prior to treatment with NUCs for at least 1 year were offered inclusion in the study. We measured liver @entity2693 using transient elastography (TE) at follow-up. TE cut-off levels to Metavir classification for @entity82 stage F2, F3 and F4 were >= 7.2 kPa, >= 8.1, and >= 11.0 kPa, respectively. RESULTS: Among 66 @entity1 with a successful TE examination at follow-up, 53 @entity1 (80%) had @entity82 and 13 had (20%) advanced @entity82 (F3) prior to treatment. Median treatment duration was 50.5 months. Among @entity1 with @entity82 prior to treatment, 26 (49%) had liver @entity2693 below 11.0 kPa at follow-up, suggesting regression of @entity82 . Among @entity1 with advanced @entity82 (F3) prior to treatment, 10 (77%) had liver @entity2693 below 8.1 kPa after treatment, suggesting improvement of @entity82 . CONCLUSION: Transient elastography examinations demonstrate that prolonged treatment with NUCs in @entity1 with @entity6194 results in low liver @entity2693 , suggesting regression of @entity82 in a majority of @entity1 with advanced @entity82 or @entity82 .
